Consortium of Multiple Sclerosis Centers (CMSC) Meeting - June 1-4, 2022 / National Harbor, MD
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 years of the Open-Label Extension to a phase 2 Trial
Montalban | Oral #DMT02
Effects of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis
Arnold | Poster #DMT17
Can a Shared Decision-Making Tool Improve Multiple Sclerosis DMT Utilization? The MS-SUPPORT Decision Aid
Col |Poster #8367
Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial
Coray | Poster #DMT39
Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Freedman |Poster #DMT40
Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
Gentile | Poster #DMT21
Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg over 2 Years) in CLARITY/CLARITY Extension: A Post Hoc Analysis of CLASSIC-MS
Giovannoni |Poster #LB
Patient Characteristics and Treatment Patterns Prior to Initiating Cladribine Tablets: a US Retrospective Commercial Claims Analysis
Kozma | Poster #DMT15
Evobrutinib Significantly Reduces Relapses and Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels
Kuhle | Poster #DMT18
Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
Mattiesing | Poster #DMT22
Quality of Life and Treatment Outcomes Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic
Nicholas | Poster #QOL16
Work Productivity Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic
Nicholas | Poster #QOL17
Cladribine Tablets After Treatment with Natalizumab (CLADRINA) Trial - Interim Analyses
Sguigna | Poster #DMT31
CLadribine Tablets: Collaborative Study to Evaluate the Impact On CNS BiomarKers in Multiple Sclerosis (CLOCK-MS) – Current Baseline Characteristics
Wu | Poster # DMT29
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: